Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines

Purpose: To identify genes involved in the paclitaxel resistance phenotype. Methods: High-density Affymetrix HG-U95Av2 microarrays were used to quantify gene expression in the resulting cell lines, SKOV-3(TR), OVCAR8(TR) and MCF-7(TR), and their drug-sensitive parental lines, SKOV-3, OVCAR8 and MCF-7. Results: Three paclitaxel-resistant human ovarian and breast cancer cell lines were established. We identified 790 (SKOV-3(TR)), 689 (OVCAR8(TR)) and 964 (MCF-7(TR)) transcripts that were more than twofold overexpressed relative to their expression in the corresponding parental cell line. A comparison of these transcripts identified eight genes that were significantly overexpressed in all three drug-resistant daughter cell lines. These genes included MDR1, a gene often implicated in both in vitro and in vivo resistance to multiple chemotherapeutics, including paclitaxel. The remaining seven genes have not been previously associated with resistance to paclitaxel in human cancer. Furthermore, we identified 815 (SKOV-3(TR)), 430 ( OVCAR8(TR)) and 332 (MCF-7(TR)) transcripts that were more than twofold decreased relative to their expression in the corresponding parental cell line. Comparison of these transcripts identified three genes that were significantly underexpressed in all three drug-resistant cell lines, none of which have been previously associated with paclitaxel resistance. Conclusions: Our results confirm that the paclitaxel resistance phenotype is associated with a large number of transcriptional changes. In addition, acquired paclitaxel resistance was associated with distinct transcriptional changes in each of the cell lines studied, suggesting that paclitaxel resistance is a complex phenotype that can arise through multiple mechanisms.